The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Pharmacological Targeting of the Transcription Factor Nrf2 at the Basal Ganglia Provides Disease Modifying Therapy for Experimental Parkinsonism
Open accessAbstract
Current therapies for motor symptoms of Parkinson's disease (PD) are based on dopamine replacement. However, the disease progression remains unaffected, because of continuous dopaminergic neuron loss. Since oxidative stress is actively involved in neuronal death in PD, pharmacological targeting of the antioxidant machinery may have therapeutic value. Here, we analyzed the relevance of the antioxidant phase II response mediated by the transcription factor NF-E2-related factor 2 (Nrf2) on brain protection against the parkinsonian toxin methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Intraperitoneal administration of the potent Nrf2 activator sulforaphane (SFN) increased Nrf2 protein levels in the basal ganglia and led to upregulation of phase II antioxidant enzymes heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase (NQO1). In wild-type mice, but not in Nrf2-knockout mice, SFN protected against MPTP-induced death of nigral dopaminergic neurons. The neuroprotective effects were accompanied by a decrease in astrogliosis, microgliosis, and release of pro-inflammatory cytokines. These results provide strong pharmacokinetic and biochemical evidence for activation of Nrf2 and phase II genes in the brain and also offer a neuroprotective strategy that may have clinical relevance for PD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
Zhang, Y., Talalay, P., Cho, C. G., & Posner, G. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2399 · Cited by 1,682
New stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940 · cited 1×
“Total numbers of neurons in the SN were calculated as described in (33).”
MethodLee, J.-M., Calkins, M. J., Chan, K., Kan, Y. W., & Johnson, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211558200 · Cited by 786
Stress-activated cap’n’collar transcription factors in aging and human disease
Sykiotis, G. P., & Bohmann, D. (2010) · Science Signaling · doi:10.1126/scisignal.3112re3 · Cited by 776 · cited 1×
“Interestingly, the transcriptional activity of Nrf2 can be restored pharmacologically in old animals (30).”
Expression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Chen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells
Li, Y., Zhang, T., Korkaya, H., Liu, S., Lee, H.-F., Newman, B., Yu, Y., Clouthier, S. G., Schwartz, S. J., Wicha, M. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2937 · Cited by 559
Direct and indirect antioxidant properties of inducers of cytoprotective proteins
Dinkova-Kostova, A. T., & Talalay, P. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700195 · Cited by 535
Cited by
Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A., & Dulak, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2223-0 · Cited by 2,632
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Self-citationSimpson, D. S. A., & Oliver, P. L. (2020) · Antioxidants · doi:10.3390/antiox9080743 · Cited by 1,044
The emerging role of Nrf2 in mitochondrial function
Dinkova-Kostova, A. T., & Abramov, A. Y. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.036 · Cited by 983
Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837
Role of Oxidative Stress in Parkinson's Disease
Hwang, O. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.11 · Cited by 835
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Self-citationSmall Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
“SFN also safeguarded dopaminergic neurons against the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and attenuated astrogliosis and microgliosis (Jazwa et al., 2011).”
BackgroundSelf-citationGlucosinolates and isothiocyanates in health and disease
Dinkova-Kostova, A. T., & Kostov, R. V. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.003 · Cited by 605
Nrf2/Keap1/ARE signaling: Towards specific regulation
Ulasov, A. V., Rosenkranz, A. A., Georgiev, G. P., & Sobolev, A. S. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120111 · Cited by 508
Rada, P., Rojo, A. I., Evrard-Todeschi, N., Innamorato, N. G., Cotte, A., Jaworski, T., Tobón-Velasco, J. C., Devijver, H., García-Mayoral, M. F., Van Leuven, F., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00180-12 · Cited by 474
Self-citationEnergy intake and exercise as determinants of brain health and vulnerability to injury and disease
Mattson, M. P. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.012 · Cited by 434
Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity
Calabrese, V., Cornelius, C., Dinkova-Kostova, A. T., Iavicoli, I., Di Paola, R., Koverech, A., Cuzzocrea, S., Rizzarelli, E., & Calabrese, E. J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.002 · Cited by 420
Activators and inhibitors of NRF2: a review of their potential for clinical development
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 413
Self-citationThe multifaceted role of Nrf2 in mitochondrial function
Holmström, K. M., Kostov, R. V., & Dinkova-Kostova, A. T. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.10.002 · Cited by 368
“…decrease in pro-inflammatory mediators (IL6 and TNFa); Nrf2−/− mice more sensitive than WT mice & no protection by SFN Rojo et al. (2010), Innamoratoet al. (2010), and Jazwa et al. (2011) [70,72,113] Parkinson’s disease Mouse _ C57BL6/SJL MPTP Nrf2−/− mice more sensitive than WT mice;…”
BackgroundInfluentialThe role of Nrf2 signaling in counteracting neurodegenerative diseases
Dinkova‐Kostova, A. T., Kostov, R. V., & Kazantsev, A. G. (2018) · The FEBS Journal · doi:10.1111/febs.14379 · Cited by 342
Nrf2—a therapeutic target for the treatment of neurodegenerative diseases
Johnson, D. A., & Johnson, J. A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.147 · Cited by 321
Cuadrado, A., Martín-Moldes, Z., Ye, J., & Lastres-Becker, I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.540633 · Cited by 320
Self-citationLu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.063 · Cited by 310
Redox Control of Microglial Function: Molecular Mechanisms and Functional Significance
Rojo, A. I., McBean, G., Cindric, M., Egea, J., López, M. G., Rada, P., Zarkovic, N., & Cuadrado, A. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5745 · Cited by 309
Self-citationNRF2 as a Therapeutic Target in Neurodegenerative Diseases
Brandes, M. S., & Gray, N. E. (2020) · ASN Neuro · doi:10.1177/1759091419899782 · Cited by 297
Angelova, P. R., Esteras, N., & Abramov, A. Y. (2021) · Medicinal Research Reviews · doi:10.1002/med.21712 · Cited by 287
Sulforaphane as a Potential Protective Phytochemical against Neurodegenerative Diseases
Tarozzi, A., Angeloni, C., Malaguti, M., Morroni, F., Hrelia, S., & Hrelia, P. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/415078 · Cited by 282
Lastres-Becker, I., García-Yagüe, A. J., Scannevin, R. H., Casarejos, M. J., Kügler, S., Rábano, A., & Cuadrado, A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6549 · Cited by 274
Self-citationMitochondrial Quality Control as a Therapeutic Target
Suliman, H. B., & Piantadosi, C. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 264
Lastres-Becker, I., Ulusoy, A., Innamorato, N. G., Sahin, G., Rábano, A., Kirik, D., & Cuadrado, A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds143 · Cited by 263
Self-citationThirty years of NRF2: advances and therapeutic challenges.
Zhang, D. D. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01145-0 · Cited by 282
The Glutathione System in Parkinson’s Disease and Its Progression
Bjørklund, G., Peana, M., Maes, M., Dadar, M., & Severin, B. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.10.004 · Cited by 186
Saha, S., Buttari, B., Profumo, E., Tucci, P., & Saso, L. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.787258 · Cited by 185
Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis
Lastres-Becker, I., Innamorato, N. G., Jaworski, T., Rábano, A., Kügler, S., Van Leuven, F., & Cuadrado, A. (2014) · Brain · doi:10.1093/brain/awt323 · Cited by 160
Self-citationEmerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders
Uddin, M. S., Mamun, A. A., Jakaria, M., Thangapandiyan, S., Ahmad, J., Rahman, M. A., Mathew, B., Abdel-Daim, M. M., & Aleya, L. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.135624 · Cited by 154
Nrf2 participates in depressive disorders through an anti-inflammatory mechanism
Martín-de-Saavedra, M. D., Budni, J., Cunha, M. P., Gómez-Rangel, V., Lorrio, S., del Barrio, L., Lastres-Becker, I., Parada, E., Tordera, R. M., Rodrigues, A. L. S., et al. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.03.020 · Cited by 143
Self-citationNatural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
Activation of Nrf2 Pathway Contributes to Neuroprotection by the Dietary Flavonoid Tiliroside
Velagapudi, R., El-Bakoush, A., & Olajide, O. A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0975-2 · Cited by 91
Castro-Sánchez, S., García-Yagüe, Á. J., Kügler, S., & Lastres-Becker, I. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101118 · Cited by 76
“Moreover, to determine whether NRF2 activation could improve this impairment, Cx3cr1 and Cx3cr1 primary microglia were treated with sulforaphane (SFN) (15 μM, 6 h), a NRF2 inducer [34].”
BackgroundMethodWang, H., Chen, G., Ahn, E. H., Xia, Y., Kang, S. S., Liu, X., Liu, C., Han, M.-H., Chen, S., & Ye, K. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-022-00430-8 · Cited by 71
Metadata
- Authors
- Jazwa, A., Rojo, A. I., Innamorato, N. G., Hesse, M., Fernández-Ruiz, J., & Cuadrado, A.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2011-06-15
- Volume
- 14
- Issue
- 12
- Pages
- 2347-2360
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W1971573216
- Cited by
- 327
- References
- 34
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.